RET and non-small cell lung carcinoma: Selpercatinib continues to be studied in several clinical trials including in the adjuvant setting in LIBRETTO-432 (NCT04819100), a randomized Phase 3 trial comparing selpercatinib with placebo in Stage IB-IIIA RET fusion–positive in NSCLC patients previously treated with definitive surgery or radiation and in LIBRETTO-121 (NCT03899792), a phase 1/2 study in 50 pediatric patients with advanced RET-altered solid or primary central nervous system tumors.